Catalog No.
Product Name
Application
Product Information
Citations
-
Autophagy Activator
501A054 is an autophagy activator that promotes autophagy-dependent cell death through the activation of autophagy pathways. This compound is valuable for research applications focused on the regulation of autophagy, particularly in the context of cervical cancer studies. Its ability to induce autophagic processes makes it a significant tool for understanding cellular mechanisms and therapeutic strategies in cancer research. -
Autophagy Activator
Soybean peptide QRPR is an autophagy activator that enhances cellular autophagy by increasing the expression and activity of key signaling proteins, including PIK3, AKT, and mTOR. This peptide has shown potential in reducing inflammatory responses, making it valuable for research in cellular stress responses and inflammatory diseases. Its role in modulating autophagy pathways positions it as an important tool for studies aimed at understanding cellular homeostasis and therapeutic interventions. -
Autophagy Inducer
Cabergoline diphosphate is an ergot alkaloid that acts as an agonist of dopamine D2-like receptors, demonstrating high affinity for D2, D3, and 5-HT2B receptors with Ki values of 0.7, 1.5, and 1.2, respectively. It serves as an autophagy inducer, making it a valuable tool for research focused on cellular processes related to autophagy and neurobiology. This compound is instrumental in studies investigating neurodegenerative diseases and metabolic regulation, providing insights into the role of dopamine receptors in cellular homeostasis. -
IKKε/TBK-1 Inhibitor
MRT67307 dihydrochloride is a potent inhibitor of IKKε and TBK-1, demonstrating IC50 values of 160 nM and 19 nM, respectively. Additionally, this compound inhibits ULK1 and ULK2 with IC50s of 45 nM and 38 nM, respectively. MRT67307 dihydrochloride plays a significant role in blocking autophagy in cellular environments, making it a valuable tool for studies involving inflammation and autophagic processes. -
Autophagy
Calmodulin-Dependent Protein Kinase II (290-309) is a specific antagonist of CaMK with a reported IC50 of 52 nM, effectively inhibiting calmodulin-dependent protein kinase II activity. This reagent plays a crucial role in the study of autophagy, facilitating research into cellular signaling pathways regulated by calcium and calmodulin. It is valuable for investigating the physiological and pathological processes influenced by CaMKII, providing insights into various diseases and potential therapeutic targets. -
Autophagy Inducer
Autophagonizer (DK-1-49) is a small molecule autophagy inducer that promotes the accumulation of autophagy-associated LC3-II while increasing the levels of autophagosomes and acidic vacuoles. This compound effectively inhibits cell viability and induces cell death in cancer cells as well as Bax/Bak double-knockout cells, demonstrating EC50 values of 3-4 μM. Autophagonizer serves as a valuable tool for research into autophagy-related processes and potential therapeutic interventions in cancer biology. -
Autophagy Inhibitor
ATG12-IN-1 is an autophagy inhibitor that effectively disrupts the ATG12-ATG3 protein-protein interaction, exhibiting an IC50 of 9 μM. This compound is valuable in cancer research, allowing for the exploration of autophagy dynamics and its implications in tumor biology. It provides a robust tool for investigating the role of autophagy in cancer progression and therapeutic resistance. -
Autophagy-Targeting Chimera
2G-HaloAUTAC is a second-generation autophagy-targeting chimera designed to enhance the efficacy of AUTACs by substituting the L-Cysteine linker with alternative structures. This compound demonstrates potent degradation activity against EGFP-HaloTag protein via an autophagic mechanism. It serves as a valuable tool for research focused on autophagy and targeted protein degradation, providing insights into cellular protein turnover processes. -
Autophagy Inhibitor
Autophagy-IN-4 (Compound 34) is a potent autophagy inhibitor, demonstrating an EC50 of 0.5 μM in U2OS cells and an LD50 of 27 μM. This compound effectively interferes with the autophagic process, making it a valuable tool for researchers investigating the role of autophagy in various biological contexts and disease models. Its specificity and efficacy support its application in studies aimed at understanding autophagy-related pathways and potential therapeutic interventions. -
Autophagy Inhibitor
Autophagy-IN-3 is an autophagy inhibitor that enhances metabolic stress within the tumor microenvironment. By inhibiting autophagic processes, it significantly increases the efficacy of cytostatics in combination therapies. This compound is particularly valuable in cancer research, where modulating autophagy can influence tumor growth and treatment response. -
Autophagy Inducer
CR-3294 is an autophagy inducer that specifically targets hypoxic cells by inhibiting inducible nitric oxide synthase (iNOS). It effectively inhibits the DNA binding activity of HIF-1alpha and reduces VEGF mRNA synthesis. This compound is valuable for research applications involving breast cancer and inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, by elucidating the role of autophagy in these conditions. -
Autophagy Inducer
SMER10 is a small-molecule autophagy inducer that enhances the formation of autophagosomes. This compound promotes the conversion of LC3-I to the autophagosome-associated form, LC3-II, thereby increasing the number of EGFP-LC3 positive structures in COS-7 and HeLa cells. SMER10 has been shown to facilitate the degradation of autophagic substrates such as the mutant huntingtin protein (EGFP-HDQ74) linked to Huntington's disease and A53T α-synuclein associated with Parkinson's disease, demonstrating its neuroprotective properties in relevant cellular models. -
Tag-Linker Conjugate
FBnG-amino-PEG3-C2-azido is a tag-linker conjugate designed to facilitate targeted protein degradation. It combines the degradation tag FBnG with a glycol linker, Amino-PEG3-C2-azido, to enhance the selective degradation of target proteins. This reagent enables the synthesis of GPX4-AUTAC and is valuable in studies of protein homeostasis and cellular responses to stress. Its versatile application is important for researchers investigating targeted therapeutic strategies in various biological contexts. -
Autophagy Inducer
Isodunnianol is a novel autophagy inducer that enhances autophagic activity by increasing the expression of pAMPK172 and pULK1555 while simultaneously reducing levels of pULK1757 and SQSTM2. This compound has demonstrated the ability to mitigate doxorubicin-induced cardiotoxicity, making it a valuable tool for research in cardioprotection and autophagy-related pathways. Its application can further advance studies related to cancer therapy and cellular stress responses. -
Autophagy Inducer
Amsacrine (gluconate) is an inhibitor of topoisomerase II, primarily functioning as an autophagy inducer. This compound exhibits significant antineoplastic activity by intercalating into the DNA of tumor cells, disrupting their replication and promoting cell death. Amsacrine (gluconate) is commonly utilized in cancer research to explore mechanisms of tumor growth inhibition and the roles of autophagy in cancer treatment. -
Autophagy Inducer
Chromomycin A2 is an autophagy inducer known for its cytotoxic properties. This compound exhibits significant anti-tumor activity, making it a valuable tool in cancer research. Its ability to modulate autophagy pathways allows for investigation into cancer cell survival and proliferation, facilitating studies focused on therapeutic interventions. -
Autophagy Activator
AR493 is an autophagy activator that targets AMPK (adenosine monophosphate-activated protein kinase). It modulates pathways involved in cellular energy sensing, leading to increased levels of autophagy. This compound is valuable for research into aging-associated disorders, including diabetes and neurodegenerative diseases, as well as for studies on autophagy regulation. -
Antitumor Agent
Antitumor agent-199 is an antitumor compound that demonstrates significant antiproliferative effects across various tumor cell lines. It effectively induces autophagy in cancer cells by activating the ATG5/ATG7 pathway. This agent is valuable for research applications focused on cancer biology and therapeutic development. -
ATG4B Inhibitor
MJO445 is a selective inhibitor of ATG4B, a key regulator in the autophagy pathway. Its inhibition of ATG4B disrupts the autophagic process in glioblastoma cells, thereby enhancing the efficacy of therapeutic strategies against this aggressive cancer. MJO445 is particularly relevant for research focused on cancer biology, autophagy modulation, and the development of novel cancer treatments. -
Autophagy Inhibitor
Autophagy-IN-C1 is a potent autophagy inhibitor that effectively inhibits the autophagic process in hepatocellular carcinoma (HCC) cells. In addition to its role in blocking autophagy, this compound also induces apoptosis, making it a valuable tool for investigating cell death mechanisms and therapeutic strategies in cancer research. Its dual activity provides insights into the interplay between autophagy and apoptosis in tumor biology. -
ULK1/ULK2 Inhibitor
SBP-5147 is a potent inhibitor of ULK1 and ULK2, exhibiting an IC50 of 2 nM for ULK1 and 53 nM for ULK2. This compound effectively inhibits the phosphorylation of Beclin-1 and Vps34, reduces autophagic flux, and downregulates the expression of key autophagy-related proteins ATG13 and ATG101. Additionally, SBP-5147 enhances MHC-I expression, induces caspase-dependent apoptosis, and decreases the viability of non-small cell lung cancer cells. Its mechanism of action makes SBP-5147 a valuable tool for research in non-small cell lung cancer and autophagy modulation. -
Autophagy Inhibitor
Autophagy-IN-7 is an autophagy inhibitor that targets the autophagic process in cells. It is primarily utilized in cancer research to investigate the effects of autophagy modulation on tumor progression and treatment response. This compound serves as a valuable tool for elucidating the role of autophagy in various cellular mechanisms and cancer biology. -
Autophagy
(1R)-cis-Bifenthrin is a synthetic pyrethroid that targets autophagy pathways, particularly affecting motor coordination. Research indicates that (1R)-cis-Bifenthrin exposure leads to decreased motor function in ParKin-/- mice, evidenced by prolonged pole climbing times and reduced wheel running activity. The compound significantly decreases the number of tyrosine hydroxylase-positive cells and alters protein expression levels. Notably, (1R)-cis-Bifenthrin promotes the expression of mitophagy-related proteins, including LC3B and p62, while demonstrating enhanced binding affinity for transferrin and transferrin receptor 2. These interactions underscore its role in mitophagy and ferroptosis-related signaling pathways. -
Autophagy Inducer
8-Nitro-cGMP is an electrophilic second messenger involved in redox signaling that acts through the formation of protein-S-cGMP adducts via the s-guanylation process. This compound serves as an inducer of autophagy, demonstrating significant biological activity in promoting RANKL-induced osteoclast differentiation from macrophages. Additionally, 8-Nitro-cGMP exhibits vasodilatory effects and has been shown to improve vascular endothelial dysfunction in diabetic mouse models, making it a valuable tool for research in cellular signaling and metabolic disorders. -
Autophagy
SW063058 is an autophagy inducer that selectively disrupts the interaction between Beclin 1 and Bcl-2, while preserving the binding of Bcl-2 to pro-apoptotic proteins such as Bax and BIM. This selective inhibition relieves the negative regulatory effects of Bcl-2 on Beclin 1, thereby enhancing autophagic activity. SW063058 promotes autophagy in vitro without inducing cytotoxicity, apoptosis, or other forms of cell death, making it a valuable tool for studying autophagic processes in various biological contexts. -
Autophagy Inhibitor
CP 53631 is an autophagy inhibitor that demonstrates anticancer activity by disrupting the autophagic process in cancer cells. This compound can also serve as an internal standard in studies examining selective serotonin reuptake inhibitors (SSRIs) such as Sertraline, making it valuable for research in antidepressant mechanisms and effects. Its dual applications in oncology and neuropharmacology underscore its significance in advancing both fields. -
TbCATL Inhibitor
CAA-0225 is a selective inhibitor of the tissue protease L, specifically targeting TbCATL with an IC50 of 1.9 nM. This compound has demonstrated significant biological activity, including the degradation of autophagosome membrane markers such as LC3-II and GABARAP. Additionally, CAA-0225 improves cardiac function in models of reperfusion injury and exhibits efficacy against Trypanosoma brucei, highlighting its potential applications in cardiovascular research and parasitology studies. -
Autophagy Activator
Autophagy activator-1 is an autophagy enhancer that promotes the autophagic process by downregulating significant members of the HSP70 family while simultaneously activating the unfolded protein response. This compound serves as a valuable tool in research focused on cellular degradation pathways, protein homeostasis, and conditions associated with autophagy dysregulation. Its application extends to studies involving neurodegenerative diseases, cancer biology, and metabolic disorders. -
Antagonist
Peptide E5 is an antagonist that targets the CXCR4/CXCL12 signaling axis. By blocking this interaction, Peptide E5 downregulates CXCR4 expression and inhibits the phosphorylation of key downstream proteins, Akt and Erk, leading to apoptosis in breast cancer cells. Additionally, Peptide E5 suppresses cellular migration and adhesion, as well as the recruitment of endothelial progenitor cells, thereby inhibiting tumor angiogenesis. This peptide is a valuable tool for research related to breast cancer and tumor microenvironment interactions. -
CXCR4 Antagonist
Peptide R analogue 10 is a potent CXCR4 antagonist, demonstrating enhanced antagonistic activity, specificity, and plasma stability compared to its predecessor, Peptide R. This compound effectively inhibits CXCL12-mediated cell migration, ERK phosphorylation, and CXCR4 internalization. Peptide R analogue 10 is valuable for research applications involving CXCR4 overexpression in models of leukemia and colon cancer. -
Autophagy Inducer
SR-3677 dihydrochloride is a selective inhibitor of Rho-associated coiled-coil containing protein kinase I (ROCK-I) and II (ROCK-II), exhibiting IC50 values of 56 nM and 3 nM, respectively. This compound serves as an autophagy inducer, promoting cellular degradation pathways that can enhance cell survival and homeostasis. It is particularly useful in research focused on cancer, neurodegenerative diseases, and metabolic disorders, where modulation of autophagy may offer therapeutic benefits. -
Bone Marrow Mesenchymal Stem Cell Inducer
Herpetin is an active lignan that functions as a bone marrow mesenchymal stem cell inducer. It activates the SDF-1/CXCR4 axis and the Wnt/β-catenin signaling pathway, promoting stem cell recruitment and differentiation. This compound is relevant for research applications focused on acute liver injury and related regenerative processes. -
CXCR4/STAT3 Inhibitor
Minecoside is a potent inhibitor of the CXCR4 receptor and STAT3 signaling pathway. It demonstrates significant anticancer and anti-inflammatory activities by downregulating CXCR4 expression and suppressing STAT3 activation, which leads to the inhibition of CXCL12-induced cellular invasion. Minecoside has been shown to effectively hinder cancer metastasis and enhance apoptosis, making it a valuable tool for research in cancer biology and therapeutic development. -
FKBP12 Targeting AUTAC
AUTAC2 is an FKBP12-targeting autophagy-mediated degrader designed to promote selective degradation of specific proteins. This compound incorporates a p-Fluorobenzyl Guanine (FBnG) moiety and an SLF ligand, which non-covalently binds to FKBP12. AUTAC2 facilitates the targeted removal of proteins through the autophagy pathway, making it a valuable tool for research applications focused on protein homeostasis and cellular regulation. -
Autophagy Inducer
Dehydropachymic acid is a triterpene derived from Poria cocos, functioning primarily as an autophagy inducer. It has demonstrated enhanced efficacy in promoting the autophagy-lysosome pathway in cells with impaired autophagic processes compared to normal cells. This compound is valuable for research applications focused on autophagy modulation and cellular homeostasis. -
Cathepsin Inhibitor
LV-320 is a potent uncompetitive inhibitor of cathepsin ATG4B, exhibiting an IC50 of 24.5 μM and a Kd of 16 μM. This compound effectively inhibits the enzymatic activity of ATG4B, thereby obstructing autophagic flux in cellular environments. Due to its stability and low toxicity, LV-320 is suitable for in vivo applications, making it a valuable tool for research on autophagy-related pathways. -
ATG4B Activator
STK683963 is an activator of the autophagy-related protein ATG4B, which plays a critical role in the regulation of autophagy and cellular homeostasis. This compound enhances ATG4B activity, contributing to the redox-regulation mechanisms within cells. STK683963 is valuable for research applications focused on cancer biology, particularly in studies investigating the modulation of autophagy pathways. -
MetAP2 Targeting AUTAC
AUTAC1 is an autophagy-mediated degrader specifically targeting MetAP2. This compound features a degradation tag and a warhead that ensures target specificity. The structure of AUTAC1 includes p-Fluorobenzyl Guanine (FBnG) and a Fumagillol moiety, with Fumagillol covalently binding to MetAP2. This compound is valuable for research applications focused on the regulation of protein degradation pathways and the study of MetAP2's role in cellular processes. -
Autophagy Inhibitor/Purinergic Receptors Antagonist
Indophagolin is a potent autophagy inhibitor targeting purinergic receptors, demonstrating an IC50 of 140 nM. It effectively antagonizes the P2X4, P2X1, and P2X3 receptors with IC50 values of 2.71, 2.40, and 3.49 μM, respectively. Additionally, Indophagolin inhibits Gq-protein-coupled P2Y4, P2Y6, and P2Y11 receptors, with IC50s ranging from 3.4 to 15.4 μM. It exhibits strong antagonistic effects on the serotonin receptor 5-HT6 (IC50=1.0 μM) and moderate effects on multiple serotonin receptors, making it a valuable tool for research into autophagy and neurological pathways. -
AUTAC4 Ligand
TSPO ligand-1 is a ligand of AUTAC4, serving as a key component in the synthesis of PROTACs. It interacts with the transmembrane structural domain protein of the mitochondrial outer membrane, facilitating the regulation of mitochondrial autophagy and promoting targeted mitochondrial renewal. Additionally, TSPO ligand-1 is implicated in the transport of cholesterol between mitochondrial membranes and serves as a sensitive biomarker for brain injury and neurodegenerative conditions. -
Autophagy Inhibitor
Autogramin-1 is a potent autophagy inhibitor that effectively suppresses autophagic processes triggered by nutrient deprivation or mTORC1 inhibition. With an IC50 of 0.17 μM against starvation-induced autophagy and 0.44 μM against Rapamycin-induced autophagy, it serves as a valuable tool for researching the role of autophagy in cellular processes and disease models. This compound provides insights into autophagic regulation and its implications in various cancer and neurodegenerative studies. -
Autophagy Inhibitor
NEO214 is an autophagy inhibitor that acts by preventing autophagy-lysosome fusion, effectively blocking autophagic flux. This compound, a covalent conjugate of the PDE4 inhibitor Rolipram and perillyl alcohol, exhibits anti-cancer activity and is capable of penetrating the blood-brain barrier. Its mechanism involves the activation of mTOR and aggregation of the transcription factor EB (TFEB), promoting the death of glioma cells. NEO214 may provide a strategy to combat chemotherapy resistance in glioblastoma. -
Atg4B Inhibitor
Atg4B-IN-2 is a selective inhibitor of Atg4B with a competitive mechanism, exhibiting a Ki value of 3.1 μM. In addition, it displays moderate inhibitory activity against phospholipase A2, with IC50 values of 11 μM and 3.5 μM for Atg4B and PLA2, respectively. This compound effectively enhances the anticancer efficacy of agents targeting castration-resistant prostate cancer through the inhibition of autophagy, making it a valuable tool for cancer research. -
Autophagy Inducer
(Rac)-BL-918 is a potent autophagy inducer that activates UNC-51-like kinase 1 (ULK1). This compound facilitates cytoprotective autophagy, making it a valuable tool for research focused on neurodegenerative diseases, particularly Parkinson's disease. Its ability to modulate autophagy pathways offers insights into therapeutic strategies for enhancing neuronal survival and function. -
Autophagy Inducer
Autophagy Inducer 4 is a Mannich base derivative of Magnolol that promotes autophagy. This compound exhibits significant anticancer properties by enhancing autophagy, leading to suppression of cancer cell viability, particularly with a 76-fold increase in cytotoxicity against T47D cells compared to Magnolol. Additionally, Autophagy Inducer 4 demonstrates inhibitory effects on the migration of T47D and HeLa cancer cells, making it a valuable reagent for cancer research. -
Peptide
PHF6 (VQIVYK) is a peptide that facilitates the self-assembly and aggregation of the full-length tau protein, specifically targeting the third microtubule-binding repeat region of tau. This peptide is instrumental in studies of tau pathology associated with neurodegenerative diseases, particularly in understanding the mechanisms underlying tau aggregation and its implications in tau-related disorders. Its unique structure makes it a valuable tool for investigating tau fibrillogenesis and potential therapeutic interventions. -
Antioxidant/Autophagy Enhancer
Thonningianin B is an antioxidant that enhances autophagy. This compound is known for its role in mitigating oxidative stress and promoting cellular renewal processes. Its ability to modulate autophagy pathways makes it a valuable reagent for research in fields such as neuroprotection, cancer biology, and age-related diseases. Thonningianin B may facilitate studies aimed at understanding the interplay between oxidative stress and cellular homeostasis. -
Autophagy Inducer
Desethylamiodarone hydrochloride is a significant active metabolite of Amiodarone, primarily functioning as an autophagy inducer. It is produced through the action of CYP3A isoenzymes and plays a critical role in cellular processes affecting autophagy. This compound is utilized in research applications focusing on cardiovascular pharmacology and cellular stress responses, due to its influence on potassium channels and potential therapeutic implications in arrhythmias. -
Autophagy Inducer
Glaucocalyxin B is an ent kaurane diterpenoid that acts as an autophagy inducer. This compound has demonstrated significant anticancer and antitumor properties, effectively reducing the growth of HL-60 cells with an IC50 of approximately 5.86 μM after 24 hours. Its mechanism and biological activity make it a valuable tool for research in cancer biology and therapeutic development. -
Autophagy Inhibitor
CUR5g is a selective autophagy inhibitor that targets the fusion of autophagosomes and lysosomes. By inhibiting the recruitment of STX17 to autophagosomes through a UVRAG-dependent mechanism, CUR5g effectively disrupts the degradation of autophagic substrates in cancer cells. This compound enhances the anticancer efficacy of Cisplatin in both in vitro and in vivo models, making it a valuable tool for studying autophagy's role in cancer treatment and potential therapeutic synergies.
